FDA nanotechnology draft guidance represents ‘marginal progress’ – petition group

US Food and Drug Administration (FDA) draft guidance on the use of nanotechnology in food and food contact substances represents only marginal progress towards regulation of the technology, a petition group has claimed.

In response to the FDA guidance, the Center for Food Safety (CFS), Friends of the Earth (FoE), the Institute for Agriculture and Trade Policy (LATP) and the International Center for Technology Assessment (ICTA) have called for the introduction of further regulations to cover the food sectors use of the technology.

The FDA document pinpointed factors that should be considered when trying to determine whether changes in manufacturing process, such as the intentional reduction in particle size to the nanoscale, can affect the safety of food.

Once finalised, Draft Guidance for Industry: Assessment the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that are Colour Additives will represent the FDAs current thinking on the topic.

The Center for Food Safety (CFS), which campaigns against harmful food production technology, has urged the FDA to issue more than just voluntary guidance on the issue.

Marginal progress

The campaigners, which are all currently working on nanotechnology oversight, have called on the FDA to further the so-far marginal progress toward regulation of products made with this new technology.

The draft guidance followed a lawsuit filed in December 2011 by the group, regarding the FDAs failure to respond to their 2006 petition. The FDA responded to the groups lawsuit in April 2012.

In its formal response to the groups lawsuit, FDA acknowledged that there are differences between nanomaterials and their bulk counterparts, and the nanomaterials have potential new risks and may require new testing, said the groups statement.

However, the agency declined to enact mandatory regulations at this time.

See the original post:

FDA nanotechnology draft guidance represents ‘marginal progress’ – petition group

Related Posts

Comments are closed.